BR112023022496A2 - Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos - Google Patents
Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentosInfo
- Publication number
- BR112023022496A2 BR112023022496A2 BR112023022496A BR112023022496A BR112023022496A2 BR 112023022496 A2 BR112023022496 A2 BR 112023022496A2 BR 112023022496 A BR112023022496 A BR 112023022496A BR 112023022496 A BR112023022496 A BR 112023022496A BR 112023022496 A2 BR112023022496 A2 BR 112023022496A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- heterocyclic compound
- medicines
- application
- same
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title 2
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 3
- -1 nitrogen-containing heterocyclic compound Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 101150063226 parp-1 gene Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110565410 | 2021-05-24 | ||
| CN202110694022 | 2021-06-22 | ||
| CN202110856289 | 2021-07-28 | ||
| CN202210198679 | 2022-03-02 | ||
| PCT/CN2022/094612 WO2022247816A1 (zh) | 2021-05-24 | 2022-05-24 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023022496A2 true BR112023022496A2 (pt) | 2024-01-16 |
Family
ID=84229501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023022496A BR112023022496A2 (pt) | 2021-05-24 | 2022-05-24 | Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240287094A1 (https=) |
| EP (1) | EP4349836A4 (https=) |
| JP (1) | JP2024519188A (https=) |
| KR (1) | KR20240012437A (https=) |
| CN (1) | CN117177971A (https=) |
| AU (1) | AU2022280845A1 (https=) |
| BR (1) | BR112023022496A2 (https=) |
| CA (1) | CA3219858A1 (https=) |
| MX (1) | MX2023013890A (https=) |
| TW (1) | TW202313630A (https=) |
| WO (1) | WO2022247816A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102867210B1 (ko) | 2021-10-01 | 2025-10-14 | 신테라, 인크. | 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| AU2023259236B2 (en) | 2022-04-28 | 2025-01-09 | Xinthera, Inc. | Tricyclic parp1 inhibitors and uses thereof |
| WO2024041643A1 (zh) * | 2022-08-25 | 2024-02-29 | 江苏恒瑞医药股份有限公司 | 稠合三环类化合物、其制备方法及其在医药上的应用 |
| CN120035596A (zh) * | 2022-11-23 | 2025-05-23 | 江苏恒瑞医药股份有限公司 | 一种含氮杂环类化合物的可药用盐、晶型及制备方法 |
| KR20260021657A (ko) | 2023-06-08 | 2026-02-13 | 상하이 센후이 메디슨 컴퍼니 리미티드 | 포름아미드계 화합물의 제조 방법 |
| WO2024255697A1 (zh) * | 2023-06-13 | 2024-12-19 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4138564A (en) * | 1977-08-03 | 1979-02-06 | American Home Products Corporation | Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| US8299256B2 (en) | 2007-03-08 | 2012-10-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
| US8404713B2 (en) | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| CN102372716A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| TWI693218B (zh) | 2014-11-14 | 2020-05-11 | 美商美國禮來大藥廠 | 極光ａ激酶抑制劑 |
| TWI715291B (zh) * | 2018-11-16 | 2021-01-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 包含parp抑制劑的藥物組合物 |
| SI3999506T1 (sl) * | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
| AU2021298145A1 (en) | 2020-06-24 | 2023-02-09 | Itf Research Pharma, S.L.U | Soft gelatin capsules |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| US11591331B2 (en) * | 2021-04-19 | 2023-02-28 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
| JP7835895B2 (ja) * | 2022-05-07 | 2026-03-25 | サイブランチ セラピューティクス カンパニー リミテッド | Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体 |
-
2022
- 2022-05-24 BR BR112023022496A patent/BR112023022496A2/pt unknown
- 2022-05-24 JP JP2024515728A patent/JP2024519188A/ja active Pending
- 2022-05-24 CA CA3219858A patent/CA3219858A1/en active Pending
- 2022-05-24 MX MX2023013890A patent/MX2023013890A/es unknown
- 2022-05-24 EP EP22810541.7A patent/EP4349836A4/en active Pending
- 2022-05-24 WO PCT/CN2022/094612 patent/WO2022247816A1/zh not_active Ceased
- 2022-05-24 TW TW111119308A patent/TW202313630A/zh unknown
- 2022-05-24 US US18/562,127 patent/US20240287094A1/en active Pending
- 2022-05-24 CN CN202280027629.8A patent/CN117177971A/zh active Pending
- 2022-05-24 KR KR1020237042926A patent/KR20240012437A/ko active Pending
- 2022-05-24 AU AU2022280845A patent/AU2022280845A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117177971A (zh) | 2023-12-05 |
| EP4349836A1 (en) | 2024-04-10 |
| TW202313630A (zh) | 2023-04-01 |
| KR20240012437A (ko) | 2024-01-29 |
| WO2022247816A1 (zh) | 2022-12-01 |
| JP2024519188A (ja) | 2024-05-08 |
| AU2022280845A1 (en) | 2023-12-14 |
| CA3219858A1 (en) | 2022-12-01 |
| US20240287094A1 (en) | 2024-08-29 |
| EP4349836A4 (en) | 2024-10-30 |
| MX2023013890A (es) | 2023-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023022496A2 (pt) | Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos | |
| MX2024004846A (es) | Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo. | |
| MX2023007853A (es) | Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo. | |
| MX2023015533A (es) | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. | |
| BR112021024674A2 (pt) | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| JOP20220271A1 (ar) | مركبات دايازينو بيريميدين كمثبطات لـ her2 | |
| CR20230404A (es) | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d | |
| BR112021023825A2 (pt) | Inibidores heterobicíclicos de mat2a e métodos de uso para tratamento de câncer | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| BR112022024120A2 (pt) | Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| BR112023001792A2 (pt) | Combinações para o tratamento de câncer | |
| BRPI0809164B8 (pt) | Composição para administração tópica e composição farmacêutica compreendendo a referida composição | |
| BR112019006047A2 (pt) | compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica | |
| SA523450286B1 (ar) | مركب 4-أمينو كوينازولين | |
| BR112022008000A2 (pt) | Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo | |
| MX2022015813A (es) | 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. | |
| BR112021018924A2 (pt) | Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento | |
| MX2024011705A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112023024741A2 (pt) | Composto de quinolinamina, método de preparação para o mesmo e aplicação do mesmo em produtos farmacêuticos | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| BR112023000817A2 (pt) | Derivado de isoindolina contendo enxofre, e método de preparação do mesmo e uso médico do mesmo | |
| MX2022011565A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| BR112021017957A2 (pt) | Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo |